Legal & General Group Plc lifted its holdings in shares of OvaScience Inc. (NASDAQ:OVAS) by 4,654.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 458,822 shares of the biotechnology company’s stock after buying an additional 449,171 shares during the period. Legal & General Group Plc owned approximately 1.29% of OvaScience worth $713,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in OVAS. LMR Partners LLP bought a new stake in OvaScience in the 2nd quarter worth about $145,000. EcoR1 Capital LLC purchased a new position in OvaScience in the 1st quarter worth about $6,568,000. Sabby Management LLC raised its position in OvaScience by 774.7% in the 1st quarter. Sabby Management LLC now owns 423,775 shares of the biotechnology company’s stock worth $792,000 after buying an additional 375,325 shares during the last quarter. KCG Holdings Inc. purchased a new position in OvaScience in the 1st quarter worth about $375,000. Finally, GMT Capital Corp raised its position in OvaScience by 43.6% in the 1st quarter. GMT Capital Corp now owns 757,114 shares of the biotechnology company’s stock worth $1,416,000 after buying an additional 229,719 shares during the last quarter. Institutional investors own 56.28% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “OvaScience Inc. (OVAS) Position Raised by Legal & General Group Plc” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/ovascience-inc-ovas-position-raised-by-legal-general-group-plc/1606704.html.

A number of analysts have recently issued reports on the stock. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of OvaScience in a report on Thursday, June 22nd. Zacks Investment Research lowered shares of OvaScience from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th.

Shares of OvaScience Inc. (OVAS) opened at 1.41 on Wednesday. The stock’s market capitalization is $50.32 million. OvaScience Inc. has a 52 week low of $1.25 and a 52 week high of $7.92. The firm’s 50-day moving average is $1.41 and its 200-day moving average is $1.48.

OvaScience (NASDAQ:OVAS) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. OvaScience had a negative net margin of 16,132.47% and a negative return on equity of 69.13%. The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. During the same quarter in the prior year, the company posted ($0.62) earnings per share. The company’s revenue for the quarter was down 55.6% compared to the same quarter last year. Analysts forecast that OvaScience Inc. will post ($1.67) earnings per share for the current fiscal year.

OvaScience Profile

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Want to see what other hedge funds are holding OVAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OvaScience Inc. (NASDAQ:OVAS).

Institutional Ownership by Quarter for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.